A Phase 1 interventional study of Saxagliptin/metformin fixed-dose combination (FDC) and Saxagliptin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in Brazil. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 39th largest by enrollment, is one of 3 that started in 2011, is one of 14 in phase 1, and was the 33rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 154th largest by enrollment of the 280 interventional ones that give a count, is one of 9 that started in 2011, is one of 86 in phase 1, and was the 199th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin extended-release (XR), 500-mg, fixed-dose combination (FDC) tablet with saxagliptin, 5-mg and metformin, 500-mg XR tablets administered together in both the fasted and fed states. In addition, to demonstrate the bioequivalence of saxagliptin and metformin in a saxagliptin, 5-mg/metformin XR, 1000-mg, FDC tablet with saxagliptin, 5-mg and metformin, 1000-mg XR tablets administered together in both the fasted and fed states.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days. Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A).
Drug: Saxagliptin/metformin fixed-dose combination (FDC) · Drug: Saxagliptin · Drug: Metformin extended-release (XR)
Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days. Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C).
Drug: Saxagliptin/metformin fixed-dose combination (FDC) · Drug: Saxagliptin · Drug: Metformin extended-release (XR)
Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days. Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E).
Drug: Saxagliptin · Drug: Saxagliptin/Metformin FDC · Drug: Metformin
Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days. Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G).
Drug: Saxagliptin · Drug: Saxagliptin/Metformin FDC · Drug: Metformin
Drug pages: Saxagliptin · Metformin
Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
Also known as: Onglyza/Glucophage extended release (XR)
Tablet, oral, 5 mg, once on Day 1 only, 1 day
Also known as: Onglyza
Tablet, oral, 500 mg, once on Day 1 only, 1 day
Also known as: Glifage XR
Drug pages: Saxagliptin · Metformin
Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
Also known as: Onglyza/Glucophage XR
Tablet, oral, 1000 mg, once on Day 1 only, 1 day
Also known as: Glifage XR
Maximum Observed Concentrations (Cmax) of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
Time frame: Days 1, 2, and 3 of Periods 1 and 2
AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])of Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
AUC=Area under the concentration-time curve
Time frame: Days 1, 2, and 3 of Periods 1 and 2
AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf]) for Metformin, Saxagliptin, and 5-Hydroxy (5-OH) Saxagliptin as a Fixed-dose Combination (FDC) and as Individual Tablets
AUC=Area Under the Concentration-time Curve
Time frame: Days 1, 2, and 3 of Periods 1 and 2
Number of Participants With Death as Outcome and Serious Adverse Events (SAEs)
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Time frame: Continuously, from screening through Day 1 to within 30 days of drug discontinuation on Day 1
| Milestone | Arm 1: Treatments A/B, B/A | Arm 2: Treatments C/D, D/C | Arm 3:Treatments E/ F, F/E | Arm 4: Treatments G/ H, H/G |
|---|---|---|---|---|
| Started | 28 | 28 | 28 | 28 |
| Completed | 26 | 26 | 25 | 25 |
| Not completed | 2 | 2 | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 | 2 | 3 |
| Withdrew: Positive test result for drugs of abuse | 1 | 0 | 0 | 0 |
| Withdrew: No longer met study criteria | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Personal reasons | 0 | 0 | 1 | 0 |
| Milestone | Arm 1: Treatments A/B, B/A | Arm 2: Treatments C/D, D/C | Arm 3:Treatments E/ F, F/E | Arm 4: Treatments G/ H, H/G |
|---|---|---|---|---|
| Started | 26 | 26 | 25 | 25 |
| Completed | 25 | 26 | 24 | 25 |
| Not completed | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| μg/mL | Sax, 5 mg/Met 500 mg XR FDC vs Individual Tablets, Fasted | Sax, 5 mg/Met 500 mg vs FDC to Individual Tablets, Fed | Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted | Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed |
|---|---|---|---|---|
| Metformin Cmax (individual tablet) | 713 ± 176 | 654 ± 118 | 1177 ± 399 | 1077 ± 139 |
| Metformin Cmax (FDC) | 678 ± 167 | 577 ± 95 | 1139 ± 325 | 1091 ± 214 |
| Saxagliptin Cmax (individual tablet) | 29274 ± 10209 | 28339 ± 7339 | 30914 ± 7965 | 31319 ± 6270 |
| Saxagliptin Cmax (FDC) | 31372 ± 11367 | 28140 ± 8311 | 33549 ± 7813 | 29545 ± 6006 |
| 5-OH Saxagliptin Cmax (individual tablets) | 54709 ± 16816 | 52628 ± 12850 | 56444 ± 14731 | 55177 ± 13751 |
| 5-OH Saxagliptin Cmax (FDC) | 56413 ± 15775 | 11316 ± 45404 | 59878 ± 15959 | 54521 ± 12319 |
AUC=Area under the concentration-time curve
| pg*h/mL | Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met, 500 mg FDC Fasting | Sax, 5 mg/Met, 500 mg: Sax, 5 mg/Met 500 mg FDC Fed | Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fasting | Sax, 5 mg/Met XR, 1000 mg: Sax, 5 mg/Met, 1000 mg FDC Fed |
|---|---|---|---|---|
| Metformin AUC(0-T) (individual tablets) | 5816 ± 1859 | 5071 ± 821 | 8174 ± 2394 | 9628 ± 3270 |
| Metformin AUC(0-T) (FDC) | 5386 ± 1896 | 4701 ± 1028 | 8500 ± 2713 | 8936 ± 2696 |
| Saxagliptin AUC(0-T) (individual tablets) | 106070 ± 26733 | 110285 ± 22139 | 102913 ± 22067 | 124536 ± 24794 |
| Saxagliptin AUC(0-T) (FDC) | 103865 ± 31088 | 109345 ± 23947 | 99215 ± 20146 | 127232 ± 28709 |
| 5-OH Saxagliptin AUC(0-T) (individual tablets) | 320743 ± 68176 | 305354 ± 53254 | 324163 ± 59358 | 9628 ± 3270 |
| 5-OH Saxagliptin AUC(0-T) (FDC) | 331332 ± 67491 | 292515 ± 45404 | 323039 ± 56031 | 8936 ± 2696 |
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
| Participants | Arm 1: Treatments A,B/B,A | Arm 2: Treatments C,D/D,C | Arm 3: Treatments E,F/ F,E | Arm 4: Treatments G,H/H,G |
|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
AUC=Area Under the Concentration-time Curve
| ng*h/mL | Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fasted | Sax, 5 mg/Met 500 mg XR FDC to Individual Tablets, Fed | Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fasted | Sax, 5 mg/Met 1000 mg XR FDC to Individual Tablets, Fed |
|---|---|---|---|---|
| Metformin AUC (0-inf) (individual tablets) | 5877 ± 1858 | 5127 ± 816 | 8338 ± 2414 | 9731 ± 3277 |
| Metformin AUC (0-inf) (FDC) | 5443 ± 1905 | 4754 ± 1037 | 8618 ± 2726 | 9054 ± 2684 |
| Saxagliptin AUC (0-inf) (individual tablets) | 107425 ± 26828 | 111677 ± 22315 | 104293 ± 22149 | 125820 ± 24856 |
| Saxagliptin AUC (0-inf) (FDC) | 105248 ± 31314 | 110705 ± 24091 | 100620 ± 20264 | 128602 ± 28729 |
| 5-OH Saxagliptin AUC (0-inf) (individual tablets) | 337345 ± 67941 | 310983 ± 53447 | 330247 ± 59863 | 332495 ± 62192 |
| 5-OH Saxagliptin AUC (0-inf) (FDC) | 326501 ± 68475 | 298037 ± 45636 | 329085 ± 56298 | 332869 ± 59469 |
Collected over From screening through Day 1 to within 30 days of drug discontinuation on Day 1. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saxagliptin, 5 mg/Metformin XR, 1000 mg Fasting | — | 0/28 (0%) | 7/28 (25%) |
| Saxagliptin, 5 mg/Metformin XR, 1000 mg Fed | — | 0/28 (0%) | 13/26 (50%) |
| Saxagliptin, 5 mg/Metformin XR, 500 mg Fasting | — | 0/28 (0%) | 10/27 (37%) |
| Saxagliptin, 5 mg/Metformin XR, 500 mg Fed | — | 0/28 (0%) | 6/26 (23.1%) |
| Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fasting | — | 0/28 (0%) | 8/25 (32%) |
| Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fed | — | 0/28 (0%) | 4/27 (14.8%) |
| Saxagliptin, 5 mg/Metformin, 500 mg FDC Fasting | — | 0/28 (0%) | 8/28 (28.6%) |
| Saxagliptin, 5 mg/Metformin, 500 mg FDC Fed | — | 0/28 (0%) | 14/28 (50%) |
| Event | Saxagliptin, 5 mg/Metformin XR, 1000 mg Fasting | Saxagliptin, 5 mg/Metformin XR, 1000 mg Fed | Saxagliptin, 5 mg/Metformin XR, 500 mg Fasting | Saxagliptin, 5 mg/Metformin XR, 500 mg Fed | Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fasting | Saxagliptin, 5 mg/Metformin, 1000 mg FDC Fed | Saxagliptin, 5 mg/Metformin, 500 mg FDC Fasting | Saxagliptin, 5 mg/Metformin, 500 mg FDC Fed |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/28 | 3/26 | 10/27 | 1/26 | 4/25 | 2/27 | 7/28 | 4/28 |
| Blood creatinine abnormalInvestigations | 0/28 | 0/26 | 0/27 | 2/26 | 0/25 | 0/27 | 0/28 | 6/28 |
| AnaemiaBlood and lymphatic system disorders | 0/28 | 1/26 | 1/27 | 1/26 | 3/25 | 0/27 | 0/28 | 1/28 |
| HypertensionVascular disorders | 1/28 | 3/26 | 0/27 | 1/26 | 0/25 | 1/27 | 2/28 | 1/28 |
| Red blood cell abnormalityBlood and lymphatic system disorders | 0/28 | 3/26 | 0/27 | 0/26 | 0/25 | 0/27 | 0/28 | 0/28 |
| VomitingGastrointestinal disorders | 3/28 | 0/26 | 0/27 | 0/26 | 0/25 | 0/27 | 0/28 | 0/28 |
| White blood cell disorderBlood and lymphatic system disorders | 1/28 | 2/26 | 0/27 | 0/26 | 1/25 | 0/27 | 0/28 | 0/28 |
| Alanine aminotransferase abnormalInvestigations | 0/28 | 2/26 | 0/27 | 0/26 | 0/25 | 0/27 | 0/28 | 0/28 |
| FlatulenceGastrointestinal disorders | 0/28 | 1/26 | 0/27 | 2/26 | 1/25 | 0/27 | 1/28 | 1/28 |
| DysgeusiaNervous system disorders | 1/28 | 0/26 | 2/27 | 0/26 | 0/25 | 0/27 | 2/28 | 0/28 |
| Age, Customized(Participants) | Arm 1: Treatments A/B, B/A | Arm 2: Treatments C/D, D/C | Arm 3:Treatments E/ F, F/E | Arm 4: Treatments G/ H, H/G | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 55 years | 28 | 28 | 28 | 28 | 112 |
| >=55 years | 0 | 0 | 0 | 0 | 0 |
| Sex/Gender, Customized(Participants) | Arm 1: Treatments A/B, B/A | Arm 2: Treatments C/D, D/C | Arm 3:Treatments E/ F, F/E | Arm 4: Treatments G/ H, H/G | Total |
|---|---|---|---|---|---|
| Both genders | 28 | 28 | 28 | 28 | 112 |
The record gives a start of Jun 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin